600511 国药股份
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入24,756,5032.55%49,696,04645,498,58446,468,60340,378,608
减:营业总成本23,626,0032.68%47,194,08943,218,51344,351,26738,790,277
    其中:营业成本23,003,3993.27%45,704,77641,676,31842,837,50037,235,801
               财务费用(52,687)135.50%(126,127)(28,840)(18,342)(6,810)
               资产减值损失(4,053)-57.07%389(5,140)(17,588)(6,479)
公允价值变动收益----10,817------
投资收益240,32821.71%358,952291,622283,351220,599
    其中:对联营企业和合营企业的投资收益243,24910.05%456,539380,800380,222327,623
营业利润1,329,6090.50%2,944,3582,694,9232,447,2741,913,218
利润总额1,317,834-0.50%2,930,8902,687,8862,444,8061,917,346
减:所得税费用254,161-2.93%596,420559,181516,303408,095
净利润1,063,6730.09%2,334,4712,128,7051,928,5031,509,251
减:非控股权益63,162-19.12%188,472164,648174,418126,562
股东净利润1,000,5111.62%2,145,9991,964,0581,754,0841,382,688

市场价值指针
每股收益 (元) *1.3261.62%2.8442.6032.3251.833
每股派息 (元) *----0.8540.7820.7000.550
每股净资产 (元) *21.37010.36%20.90918.84016.93815.167
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容